Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Nuvalent Initiates Phase 2 of ALKOVE-1 Trial for ALK-Positive NSCLC and Other Solid Tumors
Details : NVL-655 is a novel brain-penetrant ALK-selective tyrosine kinase inhibitor. It is being developed for the treatment of ALK-positive non-small cell lung cancer and other solid tumors.
Product Name : NVL-655
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : $500.0 million
Deal Type : Public Offering
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
Details : The net proceeds will be used to fund the clinical development of NVL-520 (zidesamtinib), which is being evaluated in early-stage clinical studies for the treatment of non-small cell lung cancer.
Product Name : NVL-520
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 16, 2024
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : $500.0 million
Deal Type : Public Offering
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : Undisclosed
Deal Type : Public Offering
Nuvalent Announces Public Offering of Common Stock
Details : The net proceeds will be used to fund the clinical development of NVL-520 (zidesamtinib), which is being evaluated in early-stage clinical studies for the treatment of non-small cell lung cancer.
Product Name : NVL-520
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 16, 2024
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : NVL-655
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nuvalent Updates on ALK/ ROS1 Inhibitors Supporting Best-in-Class Profiles
Details : NVL-655, a potent, brain-penetrant, ALK-selective tyrosine kinase inhibitor (TKI), demonstrated encouraging efficacy and durability in heavily pretreated ALK-positive NSCLC patients.
Product Name : NVL-655
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 09, 2024
Lead Product(s) : NVL-655
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Trial of NVL-330
Details : NVL-330 is a novel brain-penetrant HER2-selective tyrosine kinase inhibitor designed to address the combined medical need for pre-treated patients with advanced HER2-altered NSCLC.
Product Name : NVL-330
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2024
Lead Product(s) : NVL-655
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
Details : NVL-655 is a novel brain-penetrant ALK-selective tyrosine kinase inhibitor. It is being evaluated for patients with locally advanced or metastatic ALK-positive non-small cell lung cancer.
Product Name : NVL-655
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 16, 2024
Lead Product(s) : NVL-655
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
Details : NVL-520 (zidesamtinib) is a novel brain-penetrant ROS1-selective tyrosine kinase inhibitor. It is being evaluated for ROS1-positive metastatic non-small cell lung cancer.
Product Name : NVL-520
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2024
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : $300.0 million
Deal Type : Public Offering
Nuvalent Announces Pricing of Public Offering of Common Stock
Details : The net proceeds will fund clinical development and research of current or additional pipeline candidates including NVL-520, a ROS1-selective tyrosine kinase inhibitor, NVL-655, an ALK-selective inhibitor, and NVL-330, a HER2-selective tyrosine kinase in...
Product Name : NVL-520
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 16, 2023
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : $300.0 million
Deal Type : Public Offering
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NVL-520 is a brain-penetrant ROS1-selective inhibitor designed to remain active in tumors that have developed resistance to currently available ROS1 inhibitors, including tumors with the prevalent G2032R resistance mutation and those with the S1986Y/F, L...
Product Name : NVL-520
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 09, 2023
Lead Product(s) : Zidesamtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NVL-655
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NVL-655 is a brain-penetrant ALK-selective inhibitor designed to selectively inhibit wild-type ALK and its resistance variants over the structurally related TRK family to potentially avoid TRK-related CNS adverse events in patients with advanced alk-posi...
Product Name : NVL-655
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2023
Lead Product(s) : NVL-655
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable